Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.
June 28, 2018 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S. Iselin, NJ, USA, June 28, 2018 – Helsinn Therapeutics (U.S.) Inc., the U.S. subsidiary of...
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid
June 26, 2018 11:59 ET
|
Helsinn Healthcare S.A.
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid Lugano, Switzerland, June 26, 2018 – The United...